Advances in targeted cancer therapy /

Saved in:

Bibliographic Details
Imprint:	Basel ; Boston : Birkhäuser, c2005.
Description:	1 online resource (vii, 303 p.) : ill.
Language:	English
Series:	Progress in drug research ; v. 63
Subject:	Cancer -- Chemotherapy. Drug targeting. Neoplasms -- drug therapy. Antineoplastic Agents -- therapeutic use. Drug Delivery Systems. Cancer -- Chemotherapy. Drug targeting.
Format:	E-Resource Book
URL for this record:	http://pi.lib.uchicago.edu/1001/cat/bib/8877057

Hidden Bibliographic Details
Other authors / contributors:	Schultz, Richard M.
ISBN:	9783764374143 3764374144
Notes:	Includes bibliographical references. Description based on print version record.
Summary:	This volume is the first book to cover the general topic of targeted cancer therapy. It presents a range of targets such as tumor angiogenesis, cell cycle control and cell signalling, COX-2, apoptosis/cell survival, invasion and metastasis and approaches like kinase inhibitors, antisense, and antibody-based therapeutics. The emphasis is on preclinical development, including target validation, development of biomarkers, strategies for combination approaches, and development of resistance. The particular challenges involved in translating these data to clinical application are discussed.
Other form:	Print version: Advances in targeted cancer therapy. Basel ; Boston : Birkhäuser, c2005 3764371749 9783764371746

Table of Contents:

Dawn of a new era in molecular cancer therapeutics
Obstacles and opportunities in the clinical development of targeted therapeutics
Tumor models for preclinical development of targeted agents
Angiogenesis inhibitors: what is the clinical future?
Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy
Cell survival signaling during apoptosis: implications in drug resistance and anti-cancer therapeutic development
Targeted histone deacetylase inhibition for cancer prevention and therapy
Inhibitors of cyclin-dependent kinase modulators for cancer therapy
Targeting cyclooxygenase-2 for cancer prevention and treatment
Antisense approaches in drug discovery and development
Preclinical development of Alimta (Pemetrexed LY231514), a multitargeted antifolate.

Similar Items